Evidence map›Paper›PMID 22558355›Full record

ArticlePloS one2012

A novel role for the GTPase-activating protein Bud2 in the spindle position checkpoint.

Scott A Nelson, Anthony M Sanson, Hay-Oak Park, John A Cooper

Abstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Scott A NelsonDepartment of Cell Biology and Physiology, Washington University, Saint Louis, Missouri, USA.
Anthony M Sanson
Hay-Oak Park
John A Cooper

Funding

The Function of Dynein in Budding YeastR01GM047337 · NIGMS · WASHINGTON UNIVERSITY · PI COOPER, JOHN A · 1993 to 2009
$2.6M
Regulation of polarized cell growth by GTPasesR01GM076375 · NIGMS · OHIO STATE UNIVERSITY · PI PARK, HAY-OAK · 2006 to 2009
$1.3M
Septins and the Cell Cycle in Budding YeastR01GM069895 · NIGMS · WASHINGTON UNIVERSITY · PI COOPER, JOHN A · 2004 to 2009
$1.2M
NIGMS NIH HHS GM 47337NIGMS NIH HHS GM 69895NIGMS NIH HHS GM 76375NIGMS NIH HHS R01 GM047337NIGMS NIH HHS R01 GM069895NIGMS NIH HHS R01 GM076375
6 · The paper itself

Abstract

The spindle position checkpoint (SPC) ensures correct mitotic spindle position before allowing mitotic exit in the budding yeast Saccharomyces cerevisiae. In a candidate screen for checkpoint genes, we identified bud2Δ as deficient for the SPC. Bud2 is a GTPase activating protein (GAP), and the only known substrate of Bud2 was Rsr1/Bud1, a Ras-like GTPase and a central component of the bud-site-selection pathway. Mutants lacking Rsr1/Bud1 had no checkpoint defect, as did strains lacking and overexpressing Bud5, a guanine-nucleotide exchange factor (GEF) for Rsr1/Bud1. Thus, the checkpoint function of Bud2 is distinct from its role in bud site selection. The catalytic activity of the Bud2 GAP domain was required for the checkpoint, based on the failure of the known catalytic point mutant Bud2(R682A) to function in the checkpoint. Based on assays of heterozygous diploids, bud2(R682A), was dominant for loss of checkpoint but recessive for bud-site-selection failure, further indicating a separation of function. Tem1 is a Ras-like protein and is the critical regulator of mitotic exit, sitting atop the mitotic exit network (MEN). Tem1 is a likely target for Bud2, supported by genetic analyses that exclude other Ras-like proteins.

Indexed as

Cell Cycle CheckpointsGTPase-Activating ProteinsMutationSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSpindle ApparatusBUD2 protein, S cerevisiaeGTPase-Activating ProteinsSaccharomyces cerevisiae Proteins

Identifiers

PMID22558355
PMCPMC3338500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.